Reviparin sodium – a new low molecular weight heparin
Reviparin sodium – a new low molecular weight heparin
复制标题
瑞维肝素钠——一种新型低分子肝素
DOI：
10.1517/14656566.3.2.173
复制
发表时间：
2002
影响因子：
3.2
通讯作者：
H. Breddin
中科院分区：
文献类型：
--
作者：
H. Breddin
Reviparin钠（Clivarine®，Knoll AG）是一种低分子量肝素（LMWH），平均峰分子量为3900 Da。其特点是分子量分布较窄，抗Xa因子（anti-Xa）：抗IIa因子（anti-IIa）比≥3.6。在健康的人类志愿者中，与未分离肝素（UFH）相比，复肝素的血浆抗xa活性高5倍，持续时间长3倍。与UFH不同，维甲素对整体凝血试验的影响可以忽略不计。在不同的预防适应症中，Reviparin已被证明与UFH一样有效，并且引起较少的注射部位血肿。在每日剂量为1750 IU anti-Xa时，它在预防中等风险手术（一般和腹部）深静脉血栓形成（DVT）方面与UFH一样有效，并显着降低腿部支架固定患者的DVT。在每日剂量4200 IU的情况下，抗xa维甲素在预防高危骨科手术中DVT的效果与UFH或依诺肝素一样有效，在预防高危骨科手术中DVT和/或肺栓塞（PE）和/或死亡方面与UFH一样有效。在急性静脉血栓栓塞（VTE）患者中，维甲素在血栓减少方面比UFH更有效，在预防DVT和/或PE临床复发方面至少与UFH一样有效。与UFH相比，回肠肽的使用与出血并发症发生率相似或更低有关。
Reviparin sodium (Clivarine®, Knoll AG) is a low molecular weight heparin (LMWH) with a mean peak molecular weight of 3900 Da. It is characterised by a narrow molecular weight distribution profile, with an anti-factor Xa (anti-Xa):anti-factor IIa (anti-IIa) ratio of ≥ 3.6. In healthy human volunteers, plasma anti-Xa activity was up to five times higher and lasted three times longer with reviparin compared with unfractionated heparin (UFH). Unlike UFH, reviparin has negligible effects on global clotting tests. Reviparin has been shown to be as effective as UFH in different prophylactic indications and causes fewer injection-site haematomas. At a daily dose of 1750 IU anti-Xa it was as effective as UFH in preventing deep vein thrombosis (DVT) in moderate risk surgery (general and abdominal) and significantly reduced DVT in patients with brace immobilisation of the legs. At a daily dose of 4200 IU anti-Xa reviparin was as effective as UFH or enoxaparin in preventing DVT in high risk orthopaedic surgery and as effective as UFH in prevention of DVT and/or pulmonary embolism (PE) and/or mortality in high risk orthopaedic surgery. In patients with acute venous thromboembolism (VTE), reviparin was more effective than UFH in thrombus reduction and at least as effective as UFH in the prevention of clinical recurrence of DVT and/or PE. The use of reviparin is associated with a similar or lower incidence of bleeding complications than UFH.